MRVI
Maravai LifeSciences Holdings, Inc. NASDAQ Listed Nov 20, 2020$3.94
Mkt Cap $1.1B
52w Low $1.95
92.3% of range
52w High $4.11
50d MA $3.35
200d MA $3.17
P/E (TTM)
-4.1x
EV/EBITDA
-4.9x
P/B
1.4x
Debt/Equity
0.2x
ROE
-61.6%
P/FCF
-6.7x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$3.35
200d MA
$3.17
Avg Volume
1.6M
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
10770 Wateridge Circle · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | -0.07 | -0.04 | +42.9% | 3.26 | +9.8% | +9.2% | +9.2% | +10.7% | +13.2% | +17.2% | — |
| Nov 6, 2025 | AMC | -0.06 | -0.08 | -33.3% | 2.89 | -11.8% | -0.7% | +7.3% | +12.5% | +12.5% | +12.5% | — |
| Aug 11, 2025 | AMC | -0.06 | -0.08 | -33.3% | 2.06 | +13.1% | +30.6% | +33.5% | +26.2% | +26.7% | +24.8% | — |
| May 12, 2025 | AMC | -0.07 | -0.08 | -14.3% | 2.12 | +0.0% | -2.8% | -6.6% | -7.5% | -0.9% | +2.4% | — |
| Mar 18, 2025 | AMC | -0.03 | -0.06 | -100.0% | 2.58 | -0.8% | -5.8% | -7.0% | -12.0% | -13.2% | -10.9% | — |
| Nov 7, 2024 | AMC | -0.01 | -0.02 | -150.0% | 7.84 | -39.4% | -35.2% | -26.3% | -27.3% | -28.2% | -33.7% | — |
| Aug 7, 2024 | AMC | -0.04 | -0.08 | -100.0% | 9.10 | -5.4% | -6.8% | -6.2% | -4.4% | -7.3% | -9.7% | — |
| May 8, 2024 | AMC | -0.02 | -0.02 | -21.3% | 8.87 | +3.2% | +11.2% | +17.9% | +18.7% | +20.6% | +26.3% | — |
| Feb 22, 2024 | AMC | 0.00 | 0.01 | +185.2% | 5.11 | +36.0% | +63.6% | +57.1% | +61.6% | +56.9% | +51.3% | — |
| Nov 7, 2023 | AMC | -0.00 | -0.01 | -257.1% | 6.88 | -11.0% | -31.7% | -31.7% | -25.4% | -28.1% | -24.9% | — |
| Aug 7, 2023 | AMC | -0.03 | -0.06 | -100.0% | 11.02 | -14.2% | +0.7% | -2.5% | -6.5% | -6.2% | -8.8% | — |
| May 8, 2023 | AMC | 0.04 | 0.03 | -17.1% | 13.90 | -10.9% | -13.0% | -12.8% | -1.5% | +6.7% | +7.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.60 | $3.64 | +1.1% | +1.9% | -0.3% | -3.9% | -2.2% | -4.7% |
| Aug 12 | RBC Capital | Maintains | Outperform → Outperform | — | $2.06 | $2.33 | +13.1% | +30.6% | +33.5% | +26.2% | +26.7% | +24.8% |
| Aug 12 | Craig-Hallum | Maintains | Buy → Buy | — | $2.06 | $2.33 | +13.1% | +30.6% | +33.5% | +26.2% | +26.7% | +24.8% |
| May 13 | Baird | Maintains | Neutral → Neutral | — | $2.12 | $2.12 | +0.0% | -2.8% | -6.6% | -7.5% | -0.9% | +2.4% |
| May 13 | Craig-Hallum | Maintains | Buy → Buy | — | $2.12 | $2.12 | +0.0% | -2.8% | -6.6% | -7.5% | -0.9% | +2.4% |
| Mar 25 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.24 | $2.25 | +0.4% | +2.7% | +5.8% | +4.9% | +5.4% | -1.3% |
| Mar 21 | UBS | Maintains | Neutral → Neutral | — | $2.40 | $2.12 | -11.7% | -5.4% | -6.7% | -4.2% | -1.2% | -2.1% |
| Mar 3 | BofA Securities | Maintains | Buy → Buy | — | $3.22 | $3.20 | -0.6% | -6.2% | -11.8% | -12.7% | -17.1% | -8.1% |
| Feb 26 | Baird | Downgrade | Outperform → Neutral | — | $3.14 | $3.06 | -2.5% | +3.5% | -2.9% | +2.5% | -3.8% | -9.6% |
| Dec 5 | Goldman Sachs | Downgrade | Neutral → Sell | — | $5.42 | $5.18 | -4.4% | -6.1% | -6.8% | +0.2% | +9.4% | +6.5% |
| Nov 8 | William Blair | Downgrade | Outperform → Market Perform | — | $7.84 | $4.75 | -39.4% | -35.2% | -26.3% | -27.3% | -28.2% | -33.7% |
| Nov 8 | RBC Capital | Maintains | Outperform → Outperform | — | $7.84 | $4.75 | -39.4% | -35.2% | -26.3% | -27.3% | -28.2% | -33.7% |
| Nov 8 | Baird | Maintains | Outperform → Outperform | — | $7.84 | $4.75 | -39.4% | -35.2% | -26.3% | -27.3% | -28.2% | -33.7% |
| Oct 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.83 | $7.74 | -1.1% | -1.9% | -1.8% | -2.6% | +2.3% | +5.5% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $7.97 | $7.98 | +0.1% | +21.5% | +15.9% | +12.8% | +10.2% | +11.2% |
| Aug 13 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $8.70 | $8.30 | -4.6% | -3.0% | -5.5% | -8.4% | +11.3% | +6.2% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $9.10 | $8.61 | -5.4% | -6.8% | -6.2% | -4.4% | -7.3% | -9.7% |
| Aug 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.10 | $8.61 | -5.4% | -6.8% | -6.2% | -4.4% | -7.3% | -9.7% |
| Jul 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.35 | $7.35 | +0.0% | +3.0% | +5.0% | +17.0% | +21.6% | +19.2% |
| May 9 | Baird | Maintains | Outperform → Outperform | — | $8.87 | $9.15 | +3.2% | +11.2% | +17.9% | +18.7% | +20.6% | +26.3% |
| Feb 23 | Stifel | Maintains | Buy → Buy | — | $5.11 | $6.95 | +36.0% | +63.6% | +57.1% | +61.6% | +56.9% | +51.3% |
| Feb 23 | RBC Capital | Maintains | Outperform → Outperform | — | $5.11 | $6.95 | +36.0% | +63.6% | +57.1% | +61.6% | +56.9% | +51.3% |
| Dec 12 | BofA Securities | Upgrade | Neutral → Buy | — | $5.15 | $5.41 | +5.0% | +8.5% | +15.1% | +21.2% | +21.0% | +21.0% |
| Nov 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.70 | $4.76 | +1.3% | +0.0% | +9.1% | +5.3% | +10.0% | +10.4% |
| Nov 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.70 | $4.76 | +1.3% | +0.0% | +9.1% | +5.3% | +10.0% | +10.4% |
| Aug 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $11.10 | $11.12 | +0.2% | -3.2% | -7.2% | -6.8% | -9.5% | -6.5% |
| Aug 8 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $11.02 | $9.45 | -14.2% | +0.7% | -2.5% | -6.5% | -6.2% | -8.8% |
| Aug 8 | Baird | Maintains | Outperform → Outperform | — | $11.02 | $9.45 | -14.2% | +0.7% | -2.5% | -6.5% | -6.2% | -8.8% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $11.02 | $9.45 | -14.2% | +0.7% | -2.5% | -6.5% | -6.2% | -8.8% |
| Aug 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $11.02 | $9.45 | -14.2% | +0.7% | -2.5% | -6.5% | -6.2% | -8.8% |
| Aug 8 | Credit Suisse | Maintains | Neutral → Neutral | — | $11.02 | $9.45 | -14.2% | +0.7% | -2.5% | -6.5% | -6.2% | -8.8% |
| Aug 8 | Deutsche Bank | Maintains | Buy → Buy | — | $11.02 | $9.45 | -14.2% | +0.7% | -2.5% | -6.5% | -6.2% | -8.8% |
| May 23 | Credit Suisse | Downgrade | Outperform → Neutral | — | $13.60 | $12.88 | -5.3% | +0.3% | -1.5% | -2.8% | -4.0% | -4.3% |
| May 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.09 | $12.37 | +2.3% | +0.2% | +13.2% | +22.7% | +24.1% | +10.8% |
| May 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $12.09 | $12.37 | +2.3% | +0.2% | +13.2% | +22.7% | +24.1% | +10.8% |
| May 9 | Goldman Sachs | Downgrade | Buy → Neutral | — | $13.90 | $12.39 | -10.9% | -13.0% | -12.8% | -1.5% | +6.7% | +7.9% |
| May 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $13.90 | $12.39 | -10.9% | -13.0% | -12.8% | -1.5% | +6.7% | +7.9% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $13.90 | $12.39 | -10.9% | -13.0% | -12.8% | -1.5% | +6.7% | +7.9% |
| May 9 | Deutsche Bank | Maintains | Buy → Buy | — | $13.90 | $12.39 | -10.9% | -13.0% | -12.8% | -1.5% | +6.7% | +7.9% |
| Feb 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.96 | $14.61 | -2.3% | -4.0% | -3.4% | -1.4% | +0.1% | +5.4% |
| Feb 23 | Baird | Maintains | Outperform → Outperform | — | $13.83 | $16.31 | +17.9% | +8.2% | +3.8% | +4.5% | +6.7% | +8.2% |
| Feb 23 | Credit Suisse | Maintains | Outperform → Outperform | — | $13.83 | $16.31 | +17.9% | +8.2% | +3.8% | +4.5% | +6.7% | +8.2% |
| Feb 23 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $13.83 | $16.31 | +17.9% | +8.2% | +3.8% | +4.5% | +6.7% | +8.2% |
| Jan 17 | Goldman Sachs | Maintains | Buy → Buy | — | $13.83 | $13.74 | -0.7% | -0.4% | +1.4% | +0.9% | +1.6% | +4.9% |
| Jan 5 | UBS | Downgrade | Buy → Neutral | — | $13.98 | $13.24 | -5.3% | -5.2% | -5.8% | -7.1% | -2.4% | +0.2% |
| Dec 14 | Deutsche Bank | Maintains | Buy → Buy | — | $14.27 | $14.58 | +2.2% | +6.0% | +5.2% | +3.6% | -0.2% | -0.4% |
| Dec 7 | RBC Capital | Maintains | Outperform → Outperform | — | $12.50 | $12.73 | +1.8% | +1.7% | +6.4% | +6.2% | +6.4% | +14.2% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.51 | $15.50 | +6.8% | +6.9% | -2.4% | -1.8% | -7.2% | +1.4% |
| Nov 4 | Goldman Sachs | Maintains | Buy → Buy | — | $14.51 | $15.50 | +6.8% | +6.9% | -2.4% | -1.8% | -7.2% | +1.4% |
| Nov 3 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $15.36 | $13.49 | -12.2% | -5.5% | +1.0% | -7.8% | -7.2% | -12.3% |
No insider trades available.
8-K · 2.02
!! High
Maravai LifeSciences Holdings, Inc. -- 8-K 2.02: Earnings Results
Maravai LifeSciences reported Q1 2026 financial results, providing investors with updated performance metrics and operational guidance for the nucleic acid production company.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced life sciences executive is joining one of these companies, likely signaling leadership transition or strategic expansion in biotech/pharma sectors, which could impact growth direction and investor confidence.
Apr 7
8-K
Maravai LifeSciences Holdings, Inc. -- 8-K Filing
Maravai LifeSciences announced Q4 2025 results with organizational restructuring and ahead-of-plan cost reductions, signaling management's commitment to operational efficiency and profitability improvement.
Feb 25
Data updated apr 26, 2026 1:19pm
· Source: massive.com